Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection Predicts Emergence of Cross-Neutralizing Antibodies

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:34492058

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection Predicts Emergence of Cross-Neutralizing Antibodies

Jennifer M. Mabuka1, 2, 3, Anne-Sophie Dugast3, Daniel M. Muema1, 2, 4, Tarylee Reddy5, Yathisha Ramlakhan1, 2, Zelda Euler3, Nasreen Ismail2, Amber Moodley2, 3, Krista L. Dong2, 3, Lynn Morris6, 7, Bruce D. Walker2, 3, 8, 9, Galit Alter3*† and Thumbi Ndung’u1, 2, 3, 10*†

1 Africa Health Research Institute, Durban, South Africa, 2 HIV Pathogenesis Programme, Nelson R. Mandela School of Medicine, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa, 3 Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, United States, 4 KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya, 5 Biostatistics Unit, Medical Research Council, Durban, South Africa, 6 National Institute for Communicable Diseases, Johannesburg, South Africa, 7 Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 8 Howard Hughes Medical Institute, Chevy Chase, MD, United States, 9 Institute for Medical and Engineering Sciences, Massachusetts Institute of Technology, Cambridge, MA, United States, 10 Max Planck Institute for Infection Biology, Berlin, Germany

Immunological events in acute HIV-1 infection before peak viremia (hyperacute phase) may contribute to the development of broadly cross-neutralizing antibodies. Here, we used pre-infection and acute-infection peripheral blood mononuclear cells and plasma samples from 22 women, including 10 who initiated antiretroviral treatment in Fiebig stages I–V of acute infection to study B cell subsets and B-cell associated cytokines (BAFF and CXCL13) kinetics for up to ~90 days post detection of plasma viremia. Frequencies of B cell subsets were defined by flow cytometry while plasma cytokine levels were measured by ELISA. We observed a rapid but transient increase in exhausted tissue-like memory, activated memory, and plasmablast B cells accompanied by decline in resting memory cells in untreated, but not treated women. B cell subset frequencies in untreated women positively correlated with viral loads but did not predict emergence of cross-neutralizing antibodies measured 12 months post detection of plasma viremia. Plasma BAFF and CXCL13 levels increased only in untreated women, but their levels did not correlate with viral loads. Importantly, early CXCL13 but not BAFF levels predicted the later emergence of detectable cross-neutralizing antibodies at 12 months post detection of plasma viremia. Thus, hyperacute HIV-1 infection is associated with B cell subset changes, which do not predict emergence of cross-neutralizing antibodies. However, plasma CXCL13 levels during hyperacute infection predicted the subsequent emergence of cross-neutralizing antibodies, providing a potential biomarker for the evaluation of vaccines designed to elicit cross-neutralizing activity or for natural infection studies to explore mechanisms underlying development of neutralizing antibodies.

Keywords: B-cell subsets, acute HIV, CXCL13, cross-neutralizing antibodies, BAFF
INTRODUCTION

The development of a successful vaccine for HIV-1 will likely require the elicitation of broadly neutralizing antibodies (bNAb), i.e., antibodies that target fairly conserved epitopes on the HIV envelope spike and, therefore, neutralize the majority of HIV isolates; however, to date, it is not fully understood how such responses can be induced through vaccination. In natural infection, bNAb only appear after years of infection, developing in a small subset of individuals, although cross-neutralizing antibodies with narrower breadth can be detected earlier and in higher numbers of people (1–8). Thus far, plasma viral load, CD4 count and inflammation have been described as predictors of neutralizing breadth but these would be irrelevant in the context of vaccine trials (1–3, 6, 9). A report investigating bNAb lineages from early infection showed that reverted germline versions bound early autologous envelopes, potentially initiating key B cell selection processes and downstream antibody evolution pathways (10). This observation points to the potential influence of events occurring during hyperacute HIV-1 infection—before peak viremia—on development of cross-neutralizing antibodies, an area that remains unexplored to date.

In primary and chronic untreated HIV-1 infection (PHI and CHI), prior studies, largely cross-sectional in nature, have shown that B cell subset frequencies, defined by surface expression levels of CD21 and CD27, are disrupted (11, 12). Specifically, HIV-1 infected individuals have increased frequencies of immature/transitional B cells, increased tissue-like memory (TLM) B cells with signs of premature exhaustion and decreased frequencies of resting memory (RM) B cells (11–13). Although combination antiretroviral therapy (cART) initiated during chronic infection results in normalization of most B cell subsets, memory B cell defects persist and only show significant recovery if patients initiate treatment early in the course of infection (14–20). It remains unknown whether pre-infection B cell subset frequencies and changes occurring during hyperacute HIV-1 infection (or immediately following encounter with antigen following vaccination) might be used to predict the emergence of early cross-neutralizing antibodies and thus help guide vaccine strategies to drive this activity.

HIV-1 bNAb generally have unusual features including high levels of somatic hypermutation in both complementarity-determining region (CDR) loops and framework regions, long heavy chain CDR 3 (CDRH3), and a propensity toward autoreactivity (21–24). Indeed, accumulating data now show that levels of the chemokine CXCL13, produced by T follicular helper cells (Tfh), play a key role in the quality of the germinal center (GC) reaction and predict development of cross-neutralizing antibodies in HIV-infected patients (25–27). The B cell-associated cytokine B cell activating factor (BAFF) can also potentially influence the survival and class switching of unique autoreactive B cells likely to generate cross-neutralizing antibodies (28–30). Thus far, BAFF has been shown to augment development of cross-neutralizing antibodies in animal models when used as an adjuvant or supplied exogenously (31, 32) although this was not true in a cohort of subtype B infected individuals (25). Whether the levels of these two key B cell associated cytokines during hyperacute HIV-1 infection can predict subsequent development of cross-neutralizing antibodies later remains to be determined.

We sought to understand the dynamics of the B cell response, with respect to subset changes and B cell associated cytokines, prior to infection, and during hyperacute infection and how they might influence development of cross-neutralizing antibodies. Additionally, the impact of cART initiated during the acute phase of infection on these factors was evaluated. We used pre- and post-HIV-1 subtype C infection samples from young women enrolled in a study termed Females Rising through Education, Support and Health (FRESH) in the KwaZulu-Natal province of South Africa (33). We measured the dynamics of B cell subsets, plasma levels of BAFF and CXCL13 before infection and longitudinally during hyperacute HIV-1 infection and determined their influence on the emergence of cross-neutralizing antibodies at approximately 1 year postinfection (PI). Our data demonstrate that B cell defects reported in PHI and CHI emerge during hyperacute HIV-1 infection in women who do not initiate early treatment and are abrogated with immediate treatment, indicative of the influence of viral load on the observed changes. However, these dramatic B cell changes occurring in hyperacute infection did not predict the emergence of cross-neutralizing antibodies. In contrast, changes in BAFF and CXCL13 during hyperacute infection were not directly associated with viral loads. Importantly, we found higher levels of CXCL13 during hyperacute infection in individuals who subsequently developed detectable cross-neutralizing antibodies within 1 year of infection compared to those who did not. Hence our data from subtype C hyperacute infection confirm the utility of CXCL13 levels early in infection as a biomarker for possible superior GC activity associated with emergence of cross-neutralization antibodies.

MATERIALS AND METHODS

Study Population and Blood Samples

Females Rising through Education, Support and Health is a longitudinal cohort study of 18- to 23-year-old HIV-1-negative women at high risk of HIV-1 infection established in the Umlazi Township of Durban, KwaZulu-Natal, South Africa. Cohort recruitment and follow-up details have been comprehensively described elsewhere (33–35). Briefly, blood samples were obtained at study entry and every 3 months thereafter from HIV-1-negative study participants. Study subjects attended twice-weekly sessions in which trained counselors offered a comprehensive life and job skills, empowerment and HIV-1 prevention curriculum. During the twice-weekly visits, finger prick blood samples were taken for monitoring of plasma HIV-1 RNA, with results available within 24 h. Participants with a positive RNA test were contacted immediately, counseling was provided, and blood samples were collected. Subsequently, longitudinal PI venous blood samples were obtained at regular intervals through peak viremia and beyond. Peripheral blood mononuclear cells (PBMCs) were frozen from each venous blood draw for future analysis. Initially, participants identified with onset of
plasma viremia were closely monitored and referred for cART if meeting eligibility according to South African guidelines (36). Beginning July 2014, the study protocol was amended and participants with onset of HIV-1 plasma viremia were initiated on cART immediately using a standard 3-drug regimen of tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, and efavirenz 600 mg (TDF/FTC/EFZ). From July 2015, participants with acute viremia received early treatment with TDF/FTC/EFZ plus raltegravir (RAL) 400 mg twice-daily, with RAL withdrawn two months after suppression of plasma viremia to undetectable levels.

**B Cell Phenotyping**

Frozen PBMCs were thawed and allowed to rest for 2 h before being used for phenotypic analysis using a panel of fluorescently labeled monoclonal antibodies reactive with the following cell surface markers: BV711 conjugated antihuman CD3 (BioLegend, San Diego, CA, USA), BV450 mouse antihuman CD21 (BioLegend, San Diego, CA, USA), Qdot 605 mouse antihuman CD19 (Life Technologies, Carlsbad, CA, USA), PE mouse antihuman CD27 (BD Biosciences, San Jose, CA, USA), Alexa Fluor 700 mouse antihuman CD38 (BD Biosciences, San Jose, CA, USA), and aqua viability dye (Life Technologies, Carlsbad, CA, USA). Rested PBMCs were stained with 200 µl of diluted viability dye and allowed to incubate in the dark for 15 min at RT. Thereafter, cells were washed twice in phosphate-buffered saline (PBS) and then 100 µl of the cocktail of antibodies was added to 2 × 10^6 cells and incubated for 15 min at room temperature. Thereafter, tubes were washed with 3 ml PBS and centrifuged at 600 × g for 5 min. Supernatant was discarded and 100 µl of 2% paraformaldehyde was added to each tube. Samples were then acquired on the LSRFortessa (Becton Dickinson, San Jose, CA, USA) and data analyzed on FlowJo version 9.8.3 (FlowJo LLC, Ashland, OR, USA).

**Determination of Plasma BAFF and CXCL13 Levels**

BAFF and CXCL13 levels were determined by ELISA (R&D systems, Minneapolis, MN, USA) using the manufacturer's protocol. Plasma samples were thawed slowly on ice, spun down and the clear supernatant used immediately for the assays.

**Neutralization Assays**

Neutralization activity was determined using a previously described standard TZM-bl cells based assay (NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH) (37). This assay measures Tat-induced luciferase reporter gene expression after infection by HIV-1 Env-pseudotyped viruses with neutralization quantified by reduction in relative light units in TZM-bl cells in the presence of HIV-1-positive plasma. Samples were used at 1:50 dilution, and the ID50 was calculated as the reciprocal dilution at which 50% of the virus was inhibited.

**Data Analysis**

Non-parametric Spearman’s rank tests were used to test for correlations and a 2-tailed Mann–Whitney test was used to evaluate unpaired groups. Wilcoxon matched signed-rank test was used to evaluate paired samples. To assess the relationship between each B cell subset and time, varying viral load, CD4 count, BAFF, and CXCL13 adjusted for days PI, linear mixed effects models with random (subject specific) intercepts were fitted to the B cell data. Due to the complex non-linear evolution of B cell subsets over time, an unstructured mean was considered. The variables of interest (CD4 counts, viral load, CXCL13, and BAFF levels) were treated as time dependent covariates in the model, separately. B cell subsets (the outcome) were log transformed. By comparison of Akaike information criterion and Bayesian information criterion, the most suitable model was that with a random intercept and residuals which follow an autoregressive (1) structure. p-Values less than 0.05 were considered significant. Data analysis was performed in Graphpad Prism version 6 (Graphpad Software, San Diego, CA, USA) and Stata version 13.0 (Statacorp, College Station, TX, USA).

**Ethics Statement**

Study subjects provided written informed consent for participation in the study. Ethical approval was provided by the Biomedical Research Ethics Committee of the University of KwaZulu-Natal and the Institutional Review Board of Massachusetts General Hospital.

**RESULTS**

**Rapid but Transient Changes in Frequencies of B Cells and B-Cell Subsets in Acute HIV-1 Subtype C Infection**

Pre-infection samples were obtained from all participants in this study. Among the 12 untreated participants, the initial PI samples were obtained in Fiebig stage I for 11 participants and Fiebig stage III for one participant, providing us the opportunity to study very early changes in B-cell subsets and associated cytokines, and to determine how early events might influence the emergence of cross-neutralizing antibodies. Multiple samples were also obtained from participants prior to peak viremia, and during resolution of peak viremia to a viral load set-point. Ten early treated women were also studied, representing a subset of persons within our cohort who initiated standard first line treatment (TDF/FTC/EFZ) within less than 3 days of HIV-1 RNA detection. Among them, the initial PI samples were obtained in Fiebig stage I for 8 participants and Fiebig stage V for two participants. If a participant did not have a sample at 3 months after HIV-1 RNA detection, an alternative sample at 2 months was used (Figures 1 and 2).

It has previously been reported that HIV-1 uninfected people have geography- and gender-dependent differences in lymphocyte counts (38–40). We, therefore, first established the baseline (pre-infection) frequency of B cells defined as the percentage of CD3+CD19+ cells of the total live peripheral blood lymphocyte population in the 12 untreated women. We found that on average these cells accounted for 7% of the peripheral blood lymphocytes at baseline (range 3.9–12.1%), which was lower than what has been observed in geographically different cohorts from Uganda.
Following infection, three untreated individuals showed a transient increase in frequency of total B cells at days 7 and 14, although these populations decreased thereafter (Figure 3A). Overall, the median frequency of total circulating B cells was significantly lower compared to baseline pre-infection levels at 30 days ($p = 0.024$) and 90 days ($0.048$) following onset of plasma viremia (DFOPV) (Figure 3A). These data suggest that HIV-1 subtype C infection in an African population alters B cell frequencies presumably through indirect killing or redistribution of B cells, or through expansion of other lymphocyte populations, resulting in decreased proportions of B cells in the periphery over time.

The availability of pre-infection and hyperacute infection samples allowed us to determine baseline frequencies and subsequent kinetics of alterations in B cell subsets with the goal of defining early signatures associated with emergence of cross-neutralizing antibodies. Different clades of HIV-1 differ in pathogenicity and rates of disease progression. Thus, we hypothesized that the B cell kinetics in this clade C cohort might be unique if clade specific features, such as replicative capacity, are a determinant of B cell subset alterations (41–43).

We first determined the kinetics of the four previously described B cell subsets [activated memory (AM), RM, TLM, and naïve cells (11, 12)] defined by the expression of CD21 and CD27 on CD19+ mature B cells as shown in representative data (Figure 3B). There was a rapid decrease in the frequencies of RM cells (CD21+CD27+) noted at 7 DFOPV (medians; 26.55 and 16.5%, range 7–43.9 and 1–21.5% for baseline and 7 DFOPV, respectively), concurrent with an increase in TLM cells (CD21−CD27−) (medians; 12.7 and 27.85%, range 7.94–38.3 and 7.49–67.7% for baseline and 7 DFOPV, respectively). The frequencies of RM cells remained significantly lower than baseline throughout the time-points tested thereafter in the first 3 months PI ($p = 0.008$, 0.001, 0.005, and 0.019 for 7, 14, 30, and 90 DFOPV, respectively) (Figure 3C). Compared to baseline, frequencies of TLM cells were significantly higher at 7 and 14 DFOPV ($p = 0.039$ and 0.0001, respectively). Thereafter, frequencies of TLM cells remained elevated in most individuals though not statistically significant through to 90 DFOPV (Figure 3D). Importantly, neither RM nor TLM frequencies were restored to baseline values by ~90 DFOPV. We observed a significant expansion of AM cells (CD21+CD27−) by 14 DFOPV ($p = 0.005$) that persisted at 30 DFOPV ($p = 0.010$) when a peak was reached followed by contraction to near baseline values in some of the individuals by 90 DFOPV ($p = 0.083$) (Figure 3E). No changes were observed in the frequency of naïve B cells (CD21+CD27−) following HIV-1 infection (Figure 3F).
Plasmablasts (PBs) represent immunoglobulin secreting terminally differentiated B cells, which are transiently enriched in blood during infection or vaccination (44–46). To define PB kinetics in HIV-1 infection, we assessed the frequencies of CD3−CD19+CD27+CD38++ cells before and upon HIV-1 infection. At pre-infection baseline, the median frequency of PBs was 1.26% (range 0.321–11.4%) of the total B cell population. Upon infection, there was a transient expansion of the PB population as shown in the representative example (Figure 3G) that peaked by ~14 days (medians 1.26 and 6.58%, range 0.321–11.4% and 0.532–28.6% for baseline and 14 DFOPV, respectively). Following HIV-1 infection, frequencies of the PB population remained significantly elevated at all time-points tested (p = 0.016, 0.002, 0.002, and 0.019 for 7, 14, 30, and 90 DFOPV, respectively) (Figure 3H). Thus, these data illustrate that untreated subtype C acute HIV-1 infection is associated with rapid changes in frequencies of circulating B cell subsets characterized by an increased frequency of AM, TLM, and PBs but a decrease in RM cells.

**Increase in Plasma BAFF and CXCL13 Levels in Acute HIV-1 Subtype C Infection**

Given the early increase in PBs and alterations in B cell subsets, and considering that acute HIV infection has previously been associated with a cytokine storm that may have profound long-term immunological consequences (47), we next sought to determine whether there were changes following HIV infection in soluble factors associated with B cell activation, survival, and maturation. Specifically, we investigated the levels and kinetics of BAFF, a cytokine important for B cell survival, and CXCL13, a chemokine responsible for B cell trafficking to GCs and potentially responsible for the expansion of PBs (26, 48). The median plasma level of BAFF at baseline was 795 pg/ml (range 536–1,121 pg/ml). These levels increased rapidly and significantly upon infection peaking by 7 DFOPV at a median of 1,817 pg/ml (range 1,457–4,119 pg/ml, p = 0.0005) and remained significantly higher throughout the first 90 DFOPV (p = 0.005 for 14 DFOPV and p = 0.0005 for both 30 and 90 DFOPV) (Figure 4A). The median plasma CXCL13 level at baseline was 76 pg/ml (range 40–282 pg/ml). Similar to BAFF, CXCL13 levels were elevated upon infection although the increase was progressive with the highest median of 275 pg/ml (range 125–511 pg/ml) being registered 90 DFOPV (the last visit analyzed). Compared to baseline, the measurements remained significantly higher throughout the time-points analyzed in the first 90 DFOPV (p = 0.003, 0.0005, 0.0005, and 0.0039 for 3, 14, 30, and 90 DFOPV, respectively) (Figure 4B). Thus, acute HIV-1 infection is associated with rapid and gradual increase in plasma levels of B cell-associated cytokines BAFF and CXCL13, respectively.

**Viral Loads Directly Drive Changes in B Cell Subset Frequencies but not Levels of Plasma BAFF and CXCL13**

Viral loads and associated immune activation in chronic infection have been linked to changes in B cell subsets and development of bNAb s during chronic infection (9, 49, 50). To determine whether viral replication was associated with the observed changes, we first assessed the relationship between contemporaneous viral loads, CD4+ T cell counts and B cell frequencies over time. We found a negative trend and significant relationship between PBs and CD4 counts at baseline (rho = −0.52, p = 0.080) and 7 DFOPV (rho = −0.82, p = 0.023), respectively (data not shown). Next, we used linear mixed effect models to investigate
Figure 4 | Dynamics of plasma BAFF and CXCL13 levels following acute HIV-1 subtype C in absence of early antiretroviral treatment. Panels (A,B) show kinetics of BAFF and CXCL13 levels determined by ELISA using plasma samples obtained longitudinally from untreated patients within the first ~90 DFOPV and compared to matched baseline values. Horizontal lines represent median values and each color represents one patient. DFOPV, days following onset of plasma viremia. *p-Values were calculated by Wilcoxon matched signed-rank test (*p < 0.05, **p < 0.005).

Figure 3 | Frequency of B cells before and during acute HIV-1 subtype C infection in absence of early antiretroviral treatment. B cells were defined by the expression of CD19 on CD3<sup>−</sup> peripheral blood lymphocytes. B cell subsets were defined by the expression of CD27 and CD21 on CD3<sup>−</sup>CD19<sup>+</sup> lymphocytes. Plasmablasts (PBs) were defined as CD27<sup>+</sup>CD38<sup>+++</sup> cells on CD3<sup>−</sup>CD19<sup>+</sup> peripheral lymphocytes. Subsets were analyzed on longitudinal AHI samples obtained in the first ~90 DFOPV and compared to matched baseline values. Panel (A) shows a summary of the frequency of B cells as a percentage of lymphocytes overtime. Panel (B) is representative data showing B cell subsets from baseline (before infection) to ~60 DFOPV, example from participant 127-033-0097-079. Panels (C–F) represent frequencies of B cell subsets. (C) resting memory, (D) tissue-like memory, (E) activated memory, and (F) naive cells. Representative data from participant 127-033-0108-093 shows kinetics of PBs from baseline to ~90 DFOPV. (H) A comparison between frequencies of PBs at baseline and longitudinal time-points up to ~90 DFOPV. Horizontal lines represent median values and each color represents one patient. DFOPV, days following onset of plasma viremia, and time-point "0" represents baseline (visit prior to infection). *p-Values were calculated by Wilcoxon matched signed-rank test (*p < 0.05, **p < 0.005).
the overall relationship between the rapid changes in viral loads, CD4+ T cells and observed changes in B cell subset frequencies over time. Viral load was negatively associated with RM cell frequencies ($p < 0.0001$), positively associated with TLM cells ($p = 0.005$) but no significant associations with AM and PBs were observed (Table 1). In contrast, CD4+ T cell counts were positively associated with RM cells ($p = 0.001$) and negatively associated with TLM cells ($p = 0.039$) and AM cells ($p = 0.009$) (Table 1). Further, we used a model of a similar form to determine the relationship between changes in viral loads and BAFF, CXCL13, and markers of disease progression. Interestingly, there was no significant relationship between viral loads and BAFF ($p = 0.511$) or CXCL13 ($p = 0.940$). Furthermore, no association was found between CD4 cell counts and BAFF plasma levels; however, we observed a negative association between CD4+ T cell counts and CXCL13 plasma levels ($p < 0.0001$) (data not shown). We also found that BAFF levels were significantly associated with high frequencies of AM ($p = 0.006$) and PBs ($p = 0.026$) cells (Table 1). In contrast there was no significant relationship between plasma levels of CXCL13 and any B cell subset frequencies (Table 1). Taken together, these data confirm the direct relationship between viral loads and B cell subset frequencies but not BAFF and CXCL13. We, therefore, show for the first time that accumulation of TLM cells, which has mostly been associated with chronic infection, manifests within days of infection and associates with viral loads. Furthermore, the observation of a positive correlation between BAFF levels and specific B cell subsets (AM and PBs) during hyperacute HIV-1 infection may suggest a direct stimulation and/or maintenance of these subsets by this cytokine.

**Early cART Blocked Changes in B Cell Subset Frequencies and Plasma Levels of BAFF while Diminishing Changes in Levels of Plasma CXCL13**

Following our observation that changes in B cell subset frequencies are influenced by viral load, we next determined whether in the absence of persistent antigenemia the levels of the different B cell subsets, as well as B cell associated cytokines BAFF and CXCL13, would remain normal. Remarkably, there were no significant B cell subset changes observed (representative data Figures 5A,B and summary Figures 5C–E) except for an increase in PBs at 7 DFOPV ($p = 0.039$) (Figure 5F) but at lower frequencies than what was observed in untreated women (Figure 3). Indeed, frequencies of AM cells at 30 and 90 DFOPV trended toward being lower than baseline ($p = 0.109$ and 0.078, respectively, data not shown).

Furthermore, we did not observe significant changes in median plasma BAFF levels up to 90 DFOPV (Figure 6A). However, CXCL13 levels trended toward being higher upon infection and were significantly higher at 90 DFOPV compared to baseline despite complete suppression of viral loads in most of the individuals (Figure 6B). The levels of BAFF and CXCL13 were significantly different between the untreated and early treated individuals at all time-points tested except at baseline and 7 DFOPV for CXCL13 (Figures 6C,D). Our data confirm that viremia drives the changes in B cell subset frequencies, an effect that is blocked by early treatment. Furthermore, although early cART largely abrogated the cytokine surge, there was no direct relationship between viral loads and the cytokines in untreated persons, suggesting that the early cytokine responses may be induced by infection-associated changes other than viremia.

**Emergence of Cross-Neutralizing Antibodies within 1 Year of HIV-1 Subtype C Infection**

Given the rapid changes in frequencies of B cell subsets and increased levels of BAFF and CXCL13 observed during acute HIV-1 infection, we next determined whether the enrichment of a particular B cell subset or cytokine was associated with the emergence of cross-neutralizing antibodies, as an early predictor of cross-neutralization activity. We first probed for presence of cross-neutralizing antibodies for the 12 antiretroviral-naïve individuals using plasma collected at ~1 year PI. Antibody cross-neutralization activity was determined by standard TZM-bl assay against 12 viruses of different subtypes (C, B, and A) and tiers (1 and 2) (51) (Figure 7). As expected, we found that all individuals had detectable cross-neutralizing antibodies at 1 year PI against the tier 1 subtype C strain MW965 (100%) and most had activity against the tier 1 subtype B viruses MN.3 (92%) and SF162.LS (83%). One patient 127-33-0108-093 neutralized all three tier 1 viruses with the greatest potency at the time-point prior to initiation of cART (Figure 7). Among all subjects tested, a majority of subjects were able to neutralize tier 1 subtype B strains MN.3 (92%) and SF162.LS (83%).

**TABLE 1** | Linear mixed effect models for the relationship between viral loads, CD4 counts, CXCL13, and BAFF over time and B cell subsets in absence of early antiretroviral treatment.

<table>
<thead>
<tr>
<th>B cell subset</th>
<th>Activated memory</th>
<th>Resting memory</th>
<th>Tissue-like memory</th>
<th>Naive</th>
<th>Plasmablasts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viral Loads</td>
<td>Coef (SE)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.0064 (0.037)</td>
<td>−2.5253 (0.5238)</td>
<td>0.1083 (0.0388)</td>
<td>−0.3031 (1.2403)</td>
<td>0.1384 (0.0973)</td>
</tr>
<tr>
<td></td>
<td>p-Value</td>
<td>&lt;0.0001</td>
<td>0.005</td>
<td>−0.0010 (0.0005)</td>
<td>0.0756</td>
</tr>
<tr>
<td>CD4 counts</td>
<td>Coef (SE)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>−0.0006 (0.0002)</td>
<td>0.0119 (0.0035)</td>
<td>−0.0005 (0.0002)</td>
<td>0.0028 (0.0074)</td>
<td>0.0010 (0.0013)</td>
</tr>
<tr>
<td></td>
<td>p-Value</td>
<td>0.009</td>
<td>0.001</td>
<td>0.039</td>
<td>0.0026 (0.0188)</td>
</tr>
<tr>
<td>CXCL13</td>
<td>Coef (SE)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.0008 (0.0006)</td>
<td>−0.0160 (0.0106)</td>
<td>0.0007 (0.0007)</td>
<td>0.0026 (0.0188)</td>
<td>0.0010 (0.0013)</td>
</tr>
<tr>
<td></td>
<td>p-Value</td>
<td>0.207</td>
<td>0.13</td>
<td>0.309</td>
<td>0.889</td>
</tr>
<tr>
<td>BAFF</td>
<td>Coef (SE)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.0003 (0.0001)</td>
<td>−0.0015 (0.0025)</td>
<td>0.000002 (0.0001)</td>
<td>0.0038 (0.0040)</td>
<td>0.0007 (0.0003)</td>
</tr>
<tr>
<td></td>
<td>p-Value</td>
<td>0.006</td>
<td>0.553</td>
<td>0.909</td>
<td>0.373</td>
</tr>
</tbody>
</table>

Significant p values are shown in bold.
Early combination antiretroviral therapy (cART) blocks B cell subset changes. Peripheral blood mononuclear cells obtained longitudinally from eight individuals who initiated cART during Fiebig stage I–V were used to define B cell subsets and plasmablasts (PBs) by the expression of CD27, CD21, and CD27^+CD38^{+++} cells on CD3^-CD19^+ peripheral lymphocytes, respectively. B cell frequencies from the first ~90 DFOPV were compared to matched baseline values. Panels (A,B) are representative data from participant 127-033-0629-453 showing kinetics of B cell subsets and PBs, respectively, from baseline (before infection) to 90 DFOPV. Panels (C-F) represent frequencies of B cell subsets: (C) resting memory, (D) tissue-like memory, (E) activated memory, and (F) PB cells. Horizontal lines represent median values and each color represents one patient. DFOPV, days following onset of plasma viremia, and day “0” represents baseline (visit prior to infection).

To enable us to perform further analyses, individuals were categorized into those that did or did not have detectable cross-neutralization activity (regardless of the potency) against any of the tier 2 viruses tested. No activity was detected against tier 2 subtype B viruses tested. Three patients (127-33-0048-036, 127-33-0108-093, and 127-33-0450-318) had detectable but weak cross-neutralization activity against the tier 2 subtype B viruses tested. No activity was detected against tier 2 subtype A viruses at 1 year PI (Figure 7).

To enable us to perform further analyses, individuals were categorized into those that did or did not have detectable cross-neutralization activity (regardless of the potency) against any of the tier 2 viruses (6). Using this stratification, five individuals were classified as having detectable cross-neutralization activity and seven as having no detectable cross-neutralization activity (Figure 7), and these strata were used in subsequent analysis.

Plasma Levels of CXCL13 Early in Infection Predict Emergence of Cross-Neutralizing Antibodies 1 Year PI

We next investigated whether events occurring early upon infection could predict the emergence of cross-neutralizing antibodies 1 year PI. We found no differences between individuals with and without detectable cross-neutralization activity when comparing viral load set-point (p = 0.268) and contemporaneous viral loads (p = 0.404). Contemporaneous CD4 counts also did not distinguish between the two groups (p = 0.458). Notably, among individuals with detectable cross-neutralizing antibodies at 1 year, 3/5 (60%) qualified for and initiated cART due to low CD4 count within 2 years of infection compared to 2/7 (28%) of those who did not, though that relationship between emergence of cross-neutralizing antibodies and deterioration in CD4 counts was also not statistically significant (p = 0.558, Fisher’s exact test). One participant in the group with no detectable cross-neutralization was initiated on treatment outside of normal criteria due to pregnancy. To determine whether the expansion of a specific B cell subset following hyperacute infection was predictive of the emergence of cross-neutralizing antibodies, we compared the peak frequency of AM, TLM, and PBs and nadir levels of RM cells in the individuals with and without cross-neutralization activity and found no apparent differences in this small group of 12 individuals (data not shown).
Similarly, we sought to investigate whether plasma levels of CXCL13 and BAFF were associated with the emergence of cross-neutralizing antibodies. There was no significant difference between BAFF levels in the two groups at all time-points tested (data not shown). In contrast, plasma CXCL13 levels were significantly higher in those with detectable cross-neutralization activity at all early time-points tested (\( p = 0.012, 0.010, 0.030, \) and 0.018 for 7, 14, 30, and 90 DFOPV, respectively) (Figures 8A–D). Hence, high levels of CXCL13 early in infection were associated with emergence of cross-neutralizing antibodies within 1 year PI.

**DISCUSSION**

Development of an effective vaccine able to induce bNAbs remains a high priority for the HIV field but how these responses evolve in natural infection remains unclear. It has previously been reported that interactions between B cells and transmitted founder virus soon after infection likely shape the evolution of such antibodies (10). Thus understanding factors that influence the humoral response to HIV-1 early in natural infection could open new insights into designing an effective vaccine. We took advantage of a unique cohort in which specimens were available prior to HIV-1 infection and longitudinally during the earliest phases of infection, and determined the relationship between frequencies of B cell subsets and key B cell activating cytokines (BAFF and CXCL13) on the emergence of cross-neutralizing antibodies 1 year following infection. We show that in the absence of cART, the impact of HIV-1 infection is rapid and greatly impacts the frequencies of circulating RM, TLM, and PBs subsets, within 7 DFOPV. These frequencies rebounded although never to the baseline values by ~90 DFOPV which coincides with early stages of viral load set-point. These subset changes were associated with viral load in the regression analyses, confirming that viremia drives them. Plasma levels of BAFF and CXCL13 were also elevated in untreated people but did not show association with viral loads within that group. While BAFF levels showed a steady decrease after a peak on day 7, the levels of CXCL13 continued to rise and remained high 90 DFOPV possibly due to effects of immune activation or ongoing viral replication within lymphoid tissues. Frequencies of B cell subsets and plasma levels of BAFF did not influence emergence of cross-neutralizing antibodies. However, individuals with high plasma levels of CXCL13 early in infection were more likely to have detectable but weak cross-neutralizing antibodies at 1 year PI.

---

**FIGURE 6** Early combination antiretroviral therapy (cART) blocks or reduces changes in plasma levels of BAFF and CXCL13. Panels (A,B) show kinetics of BAFF and CXCL13 levels, respectively, determined by ELISA using plasma samples obtained longitudinally from 10 women who initiated cART during Fiebig stages I–V. Panels (C,D) show a comparison between kinetics of BAFF and CXCL13, respectively, between untreated and early treated women. Lines represent median values. DFOPV, days following onset of plasma viremia. \( p \)-Values for (A,B) were calculated by Wilcoxon matched signed-rank test and for (C,D) by Mann–Whitney test (\( **p < 0.005, ***p < 0.0001 \)).
CXCL13 has previously been documented to be a biomarker of the GC activity in mice, non-human primate models, vaccine recipients and HIV-1 infected people (25–27). In those studies, participants were infected with a range of subtypes but the samples tested were mainly from primary or chronic HIV-1 infection. We report a similar observation in our cohort of 12 young African women infected with HIV-1 subtype C and in hyperacute HIV-1 infection. Importantly, pre-infection samples allowed longitudinal tracking of changes following infection, clearly demonstrating that CXCL13 is induced following infection. Similar to previous reports, viral load did not have a direct influence on the CXCL13 levels in the first 60 DFOPV. However, there was a trend toward a positive correlation by 90 DFOPV, which might be an indication of a shift toward chronic infection, a period during which CXCL13 levels and viral loads correlate positively in the absence of treatment (52–55). CXCL13 plays a crucial role in the organization of B cell follicles of secondary lymphoid organs by recruiting B cells and specific T cell subsets through its receptor CXCR5 (56, 57), thus its ability to predict emergence of cross-neutralizing antibodies is not surprising.

We report a dramatic decline in frequencies of circulating RM cells that might reflect the impact of GC destruction immediately upon establishment of HIV-1 infection (5). The mechanism by which HIV-1 results in depletion of RM cells is unclear but has significant implications for maintenance of humoral immunity. Future studies need to understand whether it is active virus replication that is responsible for RM changes or a particular viral protein, and if the latter, this would suggest potential caution in the inclusion of that protein in potential immunogens to avoid unintended detrimental immunological consequences. Of note, all the observed B cell subset changes were successfully blocked by cART initiated during Fiebig stage I-V except for an initial spike of PBs, a possible reflection of GC events where infected CD4 Tfh cells may continue to stimulate B cells within the follicles before death (58).

Despite viral loads being a good predictor of development of cross-neutralizing antibodies, which are precursors for bNAbS (6), only about 25% of individuals displaying high viral loads develop bNAbS suggesting a role for other factors. The rate of depletion of CD4 T cells has also been reported to predict the development of bNAbS (2). In our study, neither viral loads nor CD4 counts predicted the emergence of cross-neutralizing antibodies at 1 year PI. However, the independent prediction by levels of CXCL13 suggests a complex multifactorial determination of the development of cross-neutralizing antibodies. Indeed, other factors, in addition to viral loads and CD4 counts, have been reported to predict the development of cross-neutralizing activity and could have influenced the associations that we observed here. For instance, early follicular helper T cell responses, measured by the frequencies of CXCR5+ CD4 T cells and which we did not assess in this study, has been show to predict of the development of neutralization breadth (25, 59). In addition, the development of bNAbS has been associated with reduced control of autoreactivity (60). Importantly, the observations reported here could be limited due to the small numbers of patients available which might preclude our ability to detect associations. Furthermore, we probed for cross-neutralizing antibodies within 1 year of infection, which is very early in the development of cross-neutralizing antibodies, and certainly before the development of any bNAbS in any of the study participants. These limitations could have also

<table>
<thead>
<tr>
<th>Subtype C Tier 1</th>
<th>Subtype B Tier 1</th>
<th>Subtype C Tier 2</th>
<th>Subtype B Tier 2</th>
<th>Subtype A Tier 2</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>PID</td>
<td>MN1</td>
<td>SF162</td>
<td>ConC</td>
<td>ZM109 Du156</td>
<td>Du151</td>
</tr>
<tr>
<td>127-33-0048-036</td>
<td>45067</td>
<td>2438</td>
<td>2260</td>
<td>106 &lt;50</td>
<td>&lt;50</td>
</tr>
<tr>
<td>127-33-0108-093*</td>
<td>15807</td>
<td>8879</td>
<td>2360</td>
<td>152 &lt;50</td>
<td>&lt;50</td>
</tr>
<tr>
<td>127-33-0251-186</td>
<td>8507</td>
<td>792</td>
<td>862</td>
<td>&lt;50 &lt;50</td>
<td>&lt;50</td>
</tr>
<tr>
<td>127-33-0450-318</td>
<td>12965</td>
<td>1329</td>
<td>1233</td>
<td>1809 77</td>
<td>&lt;50</td>
</tr>
<tr>
<td>127-33-0262-198</td>
<td>1991</td>
<td>258</td>
<td>80</td>
<td>&lt;50 &lt;50</td>
<td>&lt;50</td>
</tr>
<tr>
<td>127-33-0303-208</td>
<td>2369</td>
<td>166</td>
<td>407</td>
<td>&lt;50 &lt;50</td>
<td>&lt;50</td>
</tr>
<tr>
<td>127-33-0396-267</td>
<td>1533</td>
<td>443</td>
<td>&lt;50</td>
<td>&lt;50 &lt;50</td>
<td>&lt;50</td>
</tr>
<tr>
<td>127-33-0398-271</td>
<td>15855</td>
<td>1780</td>
<td>133</td>
<td>&lt;50 &lt;50</td>
<td>&lt;50</td>
</tr>
<tr>
<td>127-33-0097-079</td>
<td>6013</td>
<td>1341</td>
<td>846</td>
<td>&lt;50 &lt;50</td>
<td>&lt;50</td>
</tr>
<tr>
<td>127-33-0122-102</td>
<td>13690</td>
<td>135</td>
<td>400</td>
<td>&lt;50 &lt;50</td>
<td>&lt;50</td>
</tr>
<tr>
<td>127-33-0035-039</td>
<td>321</td>
<td>79</td>
<td>61</td>
<td>&lt;50 &lt;50</td>
<td>&lt;50</td>
</tr>
<tr>
<td>127-33-0442-309*</td>
<td>1650</td>
<td>&lt;50</td>
<td>&lt;50</td>
<td>&lt;50 &lt;50</td>
<td>&lt;50</td>
</tr>
</tbody>
</table>

* indicates that plasma samples tested were obtained prior to 1 year of infection. MuLV was used as the negative control. Experiments were performed at least two independent times and the mean values are reported.
reduced our ability to detect associations between B cell subsets and the emergence of cross-neutralizing antibodies.

In conclusion, acute HIV-1 subtype C infection is associated with rapid changes in B cell subsets that do not predict the emergence of cross-neutralizing antibodies within the first year of infection. Instead, our data showing an association between CXCL13 levels in acute infection and emergence of cross-neutralizing antibodies adds to growing evidence suggesting that plasma CXCL13 might be a surrogate for a functional GC compartment and serve as a biomarker to evaluate candidate vaccines for their ability to stimulate a rapid and robust GC reaction.

**ETHICS STATEMENT**

This study was carried out in accordance with the recommendations of the Biomedical Research Ethics Committee of the University of KwaZulu-Natal and the Institutional Review Board of Massachusetts General Hospital with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Biomedical Research Ethics Committee of the University of KwaZulu-Natal and the Institutional Review Board of Massachusetts General Hospital.

**AUTHOR CONTRIBUTIONS**

JM, A-SD, ZE, LM, BW, GA, and TN conceived the study. JM, YR, NI, AM, and KD participated in the acquisition of the data. JM, DM, and TR performed data analyses. JM drafted the manuscript with assistance from all authors. All authors gave the final approval for publication.

**ACKNOWLEDGMENTS**

The authors thank the study participants and the clinical and laboratory staff of the HIV Pathogenesis Programme and FRESH. We gratefully acknowledge staff from the National Institute for Communicable Diseases, particularly Dr. Carol Crowther for assistance with virus neutralization assays. Open access publication of this article has been made possible through support from the Victor Daitz Information Gateway, an initiative of the Victor Daitz Foundation and the University of KwaZulu-Natal.

**FUNDING**

This work was supported by the National Institute of Health (R37 AI080289-06A1 and R01 102660-01), the Bill and Melinda Gates Foundation CAVD (OPP1032817: Leveraging Antibody Effector
References

20. Dosenovic P, Soldemo M, Scholz JL, O'Dell S, Grasset EK, Pelletier N, et al. BLYS-mediated modulation of naive B cell subsets impacts HIV Env-induced function, the Ragon Institute of MGH, MIT and Harvard, the International AIDS Vaccine Initiative (IAVI, UKZNRSA1001), the South African Research Chairs Initiative (64809), the Victor Baillie Foundation and the Howard Hughes Medical Institute (55007427). This work was also partially supported through the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative (grant # DEL-15-006). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (grant # 107752/Z/15/Z) and the United Kingdom (UK) government. The views expressed in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government.
1200466


Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.